Four South Korean institutions signed a memorandum of understanding to build a joint AI transformation research lab focused on drug development, connecting early-stage science through clinical trials to commercialization. The partnership brings together DGIST, pharmaceutical company Yuhan, biotech firm Jeintz Bio, and the Yonsei-Yuhan Lung Cancer Research Institute.
The agreement, announced Friday, aims to accelerate AI adoption across the biotech sector and move joint research outcomes into real-world medical and industrial use. Each institution contributes a different piece of the drug development pipeline.
Who brings what
DGIST contributes AI and supercomputing capabilities alongside fundamental science research. Yuhan brings global drug development experience and a commercialization track record. Jeintz Bio adds drug candidate development experience and research execution capacity. The Yonsei-Yuhan Lung Cancer Research Institute provides patient-centered translational and clinical research expertise.
DGIST plans to extend its industrial AI transformation experience in robotics and semiconductors into biotech, building a new drug development collaboration model that combines all four institutions' expertise. The partners intend to turn unmet needs in drug development and clinical settings into concrete joint projects, linking AI-based technology development and validation through to field application and commercialization.
What the joint lab will do
The four institutions will cooperate on identifying and planning joint AI transformation research projects, integrating each institution's technologies, co-developing AI technologies and verifying their performance, and jointly planning government and private-sector R&D projects. They will also form a joint steering committee and field-specific working groups.
The partners plan to launch a joint research body tentatively called the AX Joint Research Lab, working with designated leads and dedicated researchers from each institution to finalize plans for joint projects, data sharing, and research infrastructure use.
"We will bring together DGIST's AI and supercomputing capabilities with each institution's expertise - from identifying joint projects through to verification and commercialization - to create a successful biotech AX model," DGIST President Lee Geon-woo said.
The collaboration reflects a broader push in South Korea to connect industry, academia, research institutions, and hospitals into a biotech AI ecosystem. For researchers in the field, the partnership offers a concrete example of how AI for Science & Research is moving from isolated experiments to coordinated, cross-institutional programs with defined commercialization paths.
Why this matters for science and research professionals
For scientists and researchers, this agreement signals a shift in how drug development collaborations are structured. Instead of AI being bolted onto individual research steps, the joint lab treats AI transformation as a full-cycle effort - from identifying drug candidates to validating technologies in clinical settings.
Researchers working in biotech or adjacent fields should watch how the AX Joint Research Lab handles data sharing and infrastructure access across institutions, since those decisions will shape what collaborative AI research looks like in practice. The model also suggests that institutions with AI expertise in other industries - like DGIST's work in robotics and semiconductors - will increasingly apply those methods to life sciences, which could open new cross-disciplinary research opportunities. For those looking to build relevant skills, an AI Learning Path for Research Scientists can help bridge the gap between domain expertise and the AI methods now being applied across the drug development cycle.
Your membership also unlocks:
